News
Once combined, the company will operate as HeartFlow Group and trade on the NYSE under symbol HFLO.
The proceeds will be used to fund the clinical development of MyopiaX, the company's lead product in childhood myopia.
The accelerator will be choosing projects over the next few months.
Last year the company launched a program for people with bipolar II disorder.
With HingeConnect, the platform has access to EMR data from 750,000 providers across 71,000 care sites to identify opportunities to offer users alternative care options.
The Qwalker app rewards users with redeemable points for each completed daily task.
It also introduced the newest generation of its AI wearable chip for smart health devices.
The company currently runs a telehealth platform catering to men's health, fertility health, sexual wellness and skincare.
The product's first application will be in the ultrasound market.
The Israeli company now has a total of $9 million in venture funding.